18,548 Shares in Abbott Laboratories $ABT Acquired by Old Mission Investment Co LLC

Old Mission Investment Co LLC purchased a new stake in Abbott Laboratories (NYSE:ABT) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 18,548 shares of the healthcare product maker’s stock, valued at approximately $1,683,000.

Other large investors have also recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $25,000. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at about $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in Abbott Laboratories in the 4th quarter worth about $26,000. Finally, Abound Financial LLC acquired a new stake in Abbott Laboratories in the 4th quarter worth about $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.0%

ABT stock opened at $108.29 on Monday. The firm has a 50-day moving average price of $104.43 and a 200-day moving average price of $100.03. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $187.38 billion, a P/E ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the previous year, the firm posted $1.26 EPS. The firm’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ABT. Bank of America decreased their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. TD Cowen raised their price objective on Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.